Rossari Biotech Ltd - 543213 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Compliance Certificate under Regulation 74 (5) of SEBI (Depository and Participants) Regulations, 2018 for the quarter ended December 31, 2022 Rossari Biotech Ltd - 543213 - Announcement under Regulation 30 (LODR)-Resignation of Director
Rossari Biotech Limited has informed the Exchange regarding Resignation of Mr. Robin Banerjee as Non- Executive Independent Director of the company w.e.f. January 03, 2023. Rossari Biotech Ltd - 543213 - Clarification With Respect To Increase In Volume
This is with reference to the National Stock Exchange of India Limited's Letter no. NSE/CM/Surveillance/12667, dated December 28, 2022 received through email on December 28, 2022, seeking clarification in the matter of increase in volume of equity shares of the Company, in the recent past, as traded across exchanges. Rossari Biotech Ltd - 543213 - Closure of Trading Window
Intimation of Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015 Rossari Biotech Ltd - 543213 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation of Analysts/Institutional Investor Meet/Con. Call Updates Rossari Biotech Ltd - 543213 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation of Analysts/Institutional Investor Meet/Con. Call Updates Q2FY23 Quarterly Result Announced for Rossari Biotech Ltd.
Specialty chemicals firm Rossari Biotech announced Q2FY23 results: Consolidated Q2FY23: Revenues from operations stood at Rs 425.4 crore as against Rs 434.7 crore EBITDA at Rs 56.6 crore as against Rs 57.7 crore EBITDA margin at 13.3% as against 13.3% PAT stood at Rs 23.9 crore as against Rs 28.7 crore EPS (Diluted) stood at Rs 4.32 as against Rs 5.18 Standalone Q2FY23: Revenues from operations stood at Rs 240.9 crore as against Rs 233.7 crore EBITDA at Rs 27.9 crore as against Rs 27.1 crore EBITDA margin at 11.6% as against 11.6% PAT stood at Rs 15.4 crore as against Rs 15.4 crore EPS (Diluted) stood at Rs 2.78 as against Rs 2.78 Commenting on the performance, in a joint statement, Mr. Edward Menezes, Promoter & Executive Chairman, and Mr. Sunil Chari, Promoter & Managing Director, said “We have reported a steady performance in our key business segments during the quarter amidst a volatile operating environment. Our acquired companies performed consistently during the quarter. On a consolidated basis, our total revenue from operations stood at Rs 425.4 crore in Q2 and 860.1 crore in H1. In spite of continued challenging macro economic environment and subdued global demand, we have been able to maintain our QoQ margins. On the raw material front we are now witnessing some price stability. This should help maintain our margins through the second half of the year. During the quarter, we successfully acquired an additional 15% stake in Unitop and 8% in Tristar, taking our total holding to 80% and 84% respectively. Since the acquisition, both companies have added tremendous value to Rossari, and we are very pleased with the acquisitions and the seamless integration executed by our team. Overall, we are optimistic that a stabilizing demand environment will drive sustainable growth in the upcoming quarters. To maintain our market position as a top provider of intelligent and sustainable solutions, our long-term focus will continue to be on growing our wallet share among our current client base while expanding out to emerging customer segments. The Specialty Chemicals industry in India is fast progressing with strong growth prospects for the future. With a strong balance sheet, adequate manufacturing capacities and a diversified product portfolio, we are well-poised to capitalize on the upcoming opportunities in this space.” Result PDF Rossari Biotech Ltd - 543213 - Disclosure On Related Party Transactions On Consolidated Basis For The Half Year Ended September 30, 2022
Pursuant to Regulation 23(9) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed the disclosure of Related Party Transactions on a consolidated basis, in the prescribed format, for the half year ended September 30, 2022. Rossari Biotech Ltd - 543213 - Announcement under Regulation 30 (LODR)-Credit Rating
Intimation of affirmation of Credit Rating Rossari Biotech Ltd - 543213 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Intimation of Transcript of the Q2 & FY23 Earnings Conference Call held on November 07, 2022